A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS015 In Patients With Advanced Solid Tumors
Latest Information Update: 21 Mar 2023
At a glance
- Drugs JS 015 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 21 Mar 2023 New trial record